A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.
Among 2,180 people receiving the injection, lenacapavir, there were only two cases of HIV, Gilead said in a release. Lenacapavir also proved superior in the trial to Gilead’s once-daily Truvada ...